- Report
- December 2023
- 230 Pages
Global
From €2338EUR$2,450USD£1,959GBP
- Report
- April 2023
- 110 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- July 2023
- 104 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- December 2023
- 250 Pages
Global
From €3407EUR$3,570USD£2,855GBP
The Incretin Based Drugs market is a subset of the Endocrine and Metabolic Disorders Drugs market. Incretin Based Drugs are used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or does not use insulin effectively. These drugs work by increasing the amount of insulin released by the pancreas in response to a meal, and by decreasing the amount of glucose produced by the liver. They also help to reduce appetite and slow the absorption of glucose from the intestines. Commonly prescribed Incretin Based Drugs include GLP-1 agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
Notable companies in the Incretin Based Drugs market include Novo Nordisk, Eli Lilly, Merck, AstraZeneca, and Boehringer Ingelheim. Show Less Read more